好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cortical Abnormalities and Cognitive Impairment in Pediatric MS Patients
Child Neurology and Developmental Neurology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-035
To assess cortical abnormalities in pediatric multiple sclerosis (MS) patients and their contribution to cognitive impairment.
It has been widely demonstrated that MS onset during childhood may lead to a  failure of age-expected maturation processes in the gray matter (GM) and white matter (WM), but to date only two case report studies described cortical abnormalities in pediatric MS patients.
Seventy pediatric MS patients and 26 age and sex-matched healthy controls (HC) underwent 3T MRI acquisition and clinical evaluation. Patients also underwent an extensive neuropsychological evaluation and those with > 3 abnormal tests were classified as cognitively impaired (CI). Cortical surface reconstruction and mean cortical thickness and surface area measurement were performed using FreeSurfer. Correlations between cortical abnormalities and neuropsychological and structural MRI variables were explored.

Thirteen patients were CI. Compared to HC, pediatric MS patients showed a widespread reduction of cortical surface area and thickness in bilateral brain regions belonging to frontal, parietal and temporal cortex. Significant correlations were found between reduction of cortical surface area in left frontal regions and WM lesion volume. Compared to CP, CI pediatric MS patients showed reduced surface area and thickness in frontal and parieto-occipital cortex. Different patterns of cortical abnormalities appeared to be related to the impairment at single cognitive domains, with the presence of a common core centered on the precuneus and posterior cingulate cortex.
Cortical abnormalities in strategic regions such as precuneus and cingulate cortex contribute to cognitive impairment in pediatric MS. Cortical abnormalities both in terms of cortical thinning and surface area reduction occur in these patients and are only partially related to WM lesions, suggesting the presence of early primary GM degeneration as well as an effect of the disease on cortical developmental trajectories.
Authors/Disclosures
Ermelinda De Meo (San Raffaele, Vita-Salute University, Milan)
PRESENTER 		Ms. De Meo has nothing to disclose.
Lucia Moiola, MD, PhD (Fondazione Centro San Raffaele) Dr. Moiola has nothing to disclose.
Maria P. Amato, PhD (Ospedale Di Careggi) Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOU Careggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi genzyme. The institution of Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene BMS. The institution of Dr. Amato has received research support from Merck. The institution of Dr. Amato has received research support from Biogen. The institution of Dr. Amato has received research support from Roche.
Angelo Ghezzi, MD No disclosure on file
No disclosure on file
Ruggero Capra, MD Dr. Capra has nothing to disclose.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.